AI can always write for you, but it’s not always right. That’s why JPMorgan wants to double-check its LLM’s homework. The company is seeking to patent “a method and a system for obtaining an evaluation of a quality of software code” generated by an LLM. READ ALSO: Economists Bullish on US Growth Despite Rising Inflation, Shrinking Job Market and Broadcom’s $10B Mystery Customer Underscores Ballooning AI Investments First, a user gives instructions for a task, including the output they’re looking for. The ...

NextNRG Reports Preliminary September 2025 Revenue Growth of 229% Year-Over-Year MIAMI, October 13, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – NextNRG, Inc. (NASDAQ: NXXT), a pioneer in AI-driven energy innovation transforming how energy is produced, managed, and delivered, today announced preliminary unaudited financial results for September 2025.September 2025 Highlights:Revenue: $7.07 million, up 229% year-over-year from $2.15 million in September 2024Gallons Delivered ...

Core Points - Salarius Pharmaceuticals has regained compliance with Nasdaq Listing Rule 5550(b)(1), the Equity Standard Requirement, as of October 10, 2025, following its earlier compliance with Listing Rule 5550(a)(2) on September 9, 2025 [1][2] Group 1: Compliance and Merger - The company is now fully compliant with all Nasdaq listing requirements, which is a significant step towards its planned merger with Decoy Therapeutics [2] - Salarius entered into a definitive merger agreement with Decoy Therapeutics on January 13, 2025, where Decoy will merge with a wholly owned subsidiary of Salarius, forming a new entity named Decoy Therapeutics [3] - Following the compliance notice, Salarius will be under a Mandatory Panel Monitor for one year, during which any non-compliance could lead to a delisting determination [4] Group 2: Merger Details and Pipeline - The merger is expected to create multiple value-creating opportunities through Decoy's pipeline of peptide conjugate therapeutics, which targets unmet medical needs in respiratory infectious diseases and GI oncology [5] - The combined company will focus on advancing Decoy's lead asset, a pan-coronavirus antiviral, and other programs targeting flu, COVID-19, RSV, and GI cancers [7] - Salarius' existing drug candidate, SP-3164, will be integrated into the new company's drug development strategy [5][6] Group 3: Company Backgrounds - Decoy Therapeutics is a preclinical-stage biotechnology company utilizing machine learning and AI for rapid design and manufacturing of peptide conjugate drug candidates [9] - Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company with two drug candidates focused on cancer treatment, including seclidemstat and SP-3164 [10][11]

If you found it insightful, reshare it with your network.Find me → @_avichawlaEvery day, I share tutorials and insights on DS, ML, LLMs, and RAGs.Avi Chawla (@_avichawla):This should be impossible!You can clean any ML dataset in just three lines of code. Flag outliers, find label errors, and more, across:- Any data (tabular, text, image, etc.)- Any task (classification, entity recognition, etc.)100% open-source, built by MIT researchers. https://t.co/xAaKjK4zIM ...

This should be impossible!You can clean any ML dataset in just three lines of code. Flag outliers, find label errors, and more, across:- Any data (tabular, text, image, etc.)- Any task (classification, entity recognition, etc.)100% open-source, built by MIT researchers. https://t.co/xAaKjK4zIM ...

This is the second story in our series on artificial intelligence being applied here and now, where it matters most. Last week, we brought you the story of the AI used by your doctor. This week, it's about your teacher, the one you depend on to educate your children, the one we all depend on to prepare the next generation of workers, the one that we all remember from our own childhood.-Whenever I talk to people about their experiences in education, they always name this one teacher who was so influential, a ...

RT Avi Chawla (@_avichawla)4 must-know model training paradigms for ML engineers: https://t.co/G3KunNYswt ...

PALO ALTO, Calif.--(BUSINESS WIRE)--GEICO announced today the opening of a new office in Palo Alto, placing the company at the heart of Silicon Valley innovation. This strategic location underscores GEICO's commitment to transforming the insurance industry through cutting-edge technology and attracting world-class talent. The Palo Alto office will serve as a hub for GEICO's technology initiatives, focusing on data and AI/ML engineering, product engineering, platform development, and cybersecuri. ...

Core Points - Datavault AI Inc. has regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement for its common stock [1][2] - The company's common stock maintained a closing bid price of at least $1.00 per share for ten consecutive trading days from September 26, 2025, to October 9, 2025 [2] - The resolution of this compliance issue highlights Datavault AI's commitment to maintaining its listing status and delivering value to shareholders [3] Company Overview - Datavault AI Inc. specializes in secure data tokenization and Web 3.0 innovations, offering AI-driven data experiences, valuation, and monetization [1][5] - The company operates a cloud-based platform that provides solutions across various industries, including sports & entertainment, biotech, education, fintech, real estate, healthcare, and energy [5] - Datavault AI's technology suite includes patented technologies in its Acoustic Science Division and high-performance computing solutions in its Data Science Division [5]

Core Insights - Celestica Inc. has launched two new 1.6TbE data center switches, the DS6000 and DS6001, aimed at high-bandwidth AI/ML applications, contributing to the OCP Community and listing them on the OCP Marketplace with OCP Inspired™ recognition [1][2][3] Product Specifications - The DS6000 is a 3RU, 64-port switch designed for traditional air-cooled data centers, while the DS6001 is a 2U, 64-port hybrid-cooled switch optimized for the 21-inch OCP ORv3 rack [2][4] - Both switches utilize the Broadcom Tomahawk 6 chipset, providing a total switching capacity of up to 102.4Tbps, effectively doubling the capacity compared to Celestica's existing 800G solutions [2][8] - The DS6000 and DS6001 include advanced AI routing features and interconnect options tailored for AI clusters [2][3] Market Position and Recognition - Celestica has been recognized as a leader in high-speed and AI networking, having received the 2024 Dell'Oro Market Share Leader Awards for both Ethernet Switch – AI Networks and High-Speed Networks (> 800 G) [8][9] - The introduction of the DS6000 and DS6001 switches reinforces Celestica's commitment to addressing the future needs of AI networking and its understanding of enterprise customer requirements for reliability and performance [9][10] Industry Collaboration - The new switches will be showcased at the OCP Global Summit 2025, highlighting Celestica's role in the open networking ecosystem [6][7] - The collaboration with Broadcom on the Tomahawk 6 chipset emphasizes the innovation in delivering solutions optimized for modern AI workloads [7][8] Customer Benefits - The DS6000 and DS6001 switches offer significant advantages, including high performance, energy efficiency, and flexibility in port speeds ranging from 50GbE to 800GbE [8][9] - Both switches support an open-source Network Operating System (NOS) approach, enhancing deployment versatility across various use cases [5][6]